FGFR2 and intrahepatic cholangiocarcinoma: However, patients often develop acquired resistance to these inhibitors through the emergence of secondary kinase-activating mutations, as observed in FGFR2 fusion-driven intrahepatic cholangiocarcinoma [13, 38].